T-Cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs

Andréa Barbosa de Melo¹, Eduardo J. M. Nascimento², Ulisses Braga-Neto³, Rafael Dhalia¹, Ana Maria Silva¹, Mathias Oelke⁴, Jonathan P. Schneck⁵, John Sidney⁵, Alessandro Sette⁵, Silvia M. L. Montenegro⁶, Ernesto T. A. Marques¹,²,⁶

¹Virology and Experimental Therapeutics Laboratory, Aggeu Magalhães Research Center, Fiocruz, Recife, Pernambuco, Brazil, ²Center for Vaccine Research, Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, ³Department of Electrical and Computer Engineering, Texas A&M University, College Station, Texas, United States of America, ⁴Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, ⁵La Jolla Institute for Allergy and Immunology, Vaccine Discovery, La Jolla, California, United States of America, ⁶Department of Immunology, Aggeu Magalhães Research Center, Fiocruz, Recife, Pernambuco, Brazil

Abstract

The yellow fever vaccines (YF-17D-204 and 17DD) are considered to be among the safest vaccines and the presence of neutralizing antibodies is correlated with protection, although other immune effector mechanisms are known to be involved. T-cell responses are known to play an important role modulating antibody production and the killing of infected cells. However, little is known about the repertoire of T-cell responses elicited by the YF-17DD vaccine in humans. In this report, a library of 653 partially overlapping 15-mer peptides covering the envelope (Env) and nonstructural (NS) proteins 1 to 5 of the vaccine was utilized to perform a comprehensive analysis of the virus-specific CD4⁺ and CD8⁺ T-cell responses. The T-cell responses were screened ex-vivo by IFN-γ ELISPOT assays using blood samples from 220 YF-17DD vaccinees collected two months to four years after immunization. Each peptide was tested in 75 to 208 separate individuals of the cohort. The screening identified sixteen immunodominant antigens that elicited activation of circulating memory T-cells in 10% to 33% of the individuals. Biochemical in-vitro binding assays and immunogenetic and immunogenicity studies indicated that each of the sixteen immunogenic 15-mer peptides contained two or more partially overlapping epitopes that could bind with high affinity to molecules of different HLAs. The prevalence of the immunogenicity of a peptide in the cohort was correlated with the diversity of HLA-II alleles that they could bind. These findings suggest that overlapping of HLA binding motifs within a peptide enhances its T-cell immunogenicity and the prevalence of the response in the population. In summary, the results suggest that addition to factors of the innate immunity, “promiscuous” T-cell antigens might contribute to the high efficacy of the yellow fever vaccines.

Introduction

The yellow fever (YF) vaccines (YF-17D-204 and 17DD) are considered to be among the most effective vaccines [1,2]. Antibody and T-cell responses are believed to mediate protection [3,4,5], and recent studies have also implicated the innate immune responses as one of the critical elements for developing the immune responses [6]. However, the immune adaptive mechanisms that make this vaccine so highly effective are unclear. T-cell immune responses against YF wild type virus and other flaviviruses, such as dengue and West Nile virus [7,8], are considered to be important for development of neutralizing antibodies, and activation of CD4⁺ helper T-cells and CD8⁺ cytotoxic T lymphocytes (CTLs) against YF wild type virus has been reported [6,9,10]. The CTL responses appear 14 days after vaccination and these cells differentiate into long-lived memory T-cells after a few months [11]; however, only a few YF wild type virus T-cell epitopes have been described in humans [12,13].

In order to expand the repertoire of human leukocyte antigens (HLA) restricted YF wild type virus epitopes, and as part of the Immune Epitope Database - IEDB program (http://www.immuneepitope.org/), we studied the repertoire of T-cell responses present in a cohort of YF-17DD vaccinees established by Melo et al. [14] and identified 16 peptides that are immunogenic in more than 10% of the individuals tested. Analysis of the most prevalent immunogenic peptides indicated that they contain overlapping HLA binding motifs and suggested that the prevalence T-cell immunogenicity in response to YF vaccine (17DD) is correlated with the ability of the peptide to bind multiple HLA types.
**Author Summary**

T-cell responses are considered to be very important; however, the role of T-cell responses in vaccine mediated immunity is still controversial. One reason may be that most studies of human T-cell responses are focused on a few epitopes. We still lack a systematic view of the repertoire of peptides presented by the different HLA class I and II molecules and how the peptides presented by the different HLAs interact within the host to develop T-cell responses. Here we present a study of the T-cell responses against the YF-17DD vaccine in the context of a cohort of 220 volunteers and observed that the most prevalent T-cell responses are targeted at peptides that bind to multiple types of HLA molecules. Based on these results we postulate that promiscuous T-cell epitopes might have a critical role in the development of adaptive immunity. These results may have broader implications for other pathogens, since the yellow fever vaccine is currently being developed as a vaccine vector for other diseases. Therefore, these epitopes might have a functionally cooperative role in boosting specific neutralizing antibody responses. In addition, we propose that promiscuous T-cell antigens may be better immunogens for vaccine development; however more studies are necessary.

**Materials and Methods**

**Ethics statement**

This study was reviewed and approved by the ethics committee of the Brazilian Ministry of Health (CONEP: 12138; Process n° 25000.103608/2005-39). In addition, the Johns Hopkins University and University of Pittsburgh Institutional Review Boards also reviewed and approved this study as protocol JHM-IRB-3: 03-08-27-01 and PRO09090146 respectively. Written informed consent was obtained from all volunteers and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki.

**Study Population**

A cohort of YF-17DD vaccinees was established and described elsewhere [14]. Briefly, healthy subjects, IgG-negative for YFV, were immunized with the YF-17DD vaccine (Biomanguinhos, Oswaldo Cruz Foundation, Brazil) at The Brazilian National Health Surveillance Agency (ANVISA) office, International Airport of Recife. After a full explanation of the study, written consent was obtained from each volunteer and blood samples were collected before (Day 0, used as negative controls) and after vaccination (2 months to 4 years).

**Blood Collection and Isolation of Peripheral Blood Mononuclear Cells (PBMCs)**

Blood samples were collected from 220 subjects into 10 mL Vacutainer® tubes (Becton Dickinson, Franklin Lakes, NJ). Serum was obtained by centrifuging the whole blood at 1,600 ×g for 10 min and aliquots (1 mL per tube) were stored at −20°C for further use on serological tests. For harvesting PBMC, blood samples collected in heparin Vacutainer® tubes (Becton Dickinson, Franklin Lakes, NJ) were used. Isolation of PBMC was carried out through gradient density using Ficoll-Paque™ PLUS (Amersham Biosciences Ab, Uppsala, Sweden) according to the protocol suggested by the manufacturer. Residual red blood cells were lysed with Ammonium-Chloride-Potassium lysis buffer (Gibco BRL, Gaithersburg, MD) for 3 min at room temperature. Then, cells were resuspended in Hybridoma Serum Free Media (SFM; Gibco BRL, Gaithersburg, MD) for ELISPOT assaying.

**CD4+ T-Cell Depletion**

PBMC samples from at least 3 subjects, known to respond against the peptides Env57-71, Env345-359, Env361-375, NS3137-151, NS4b7-91, NS341-455, NS545-539, NS560-679 and NS5441-495 were depleted of CD4+ T-cells using anti-CD4 mAb coated microbeads (Miltenyi Biotec, Auburn, CA) and LD columns (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s directions. This approach consistently yielded cell samples in which depletion was greater than 95% for CD4+ T-cells, according to flow cytometry analysis (data not shown).

**Isolation of CD8+ T-Cells**

CD8+ T-cells were isolated from PBMC samples by the negative selection method using the isolation kits and LS columns provided by Miltenyi Biotec (Auburn, CA), according to the manufacturer’s manual. This approach consistently yielded cell samples in which purity was greater than 90% for CD8+ T-cells according to flow cytometer analysis (data not shown).

**Peptide Library**

To measure the breadth and magnitude of T-cell responses, a library of 653 peptides (15-mers), overlapping by 11 amino acids, spanning the length of the 17DD YFV proteins Env (n = 120), NS1 (n = 47), NS2a (n = 32), NS2b (n = 28), NS3 (n = 148), NS4a (n = 43), NS4b (n = 17) and NS5 (n = 216) (sequence NCBI entry U17066) was synthesized by Schafer-N (Copenhagen, Denmark). These peptides were HPLC-purified to 80% purity or greater, with the exception of four peptides that could not be purified and were used as crude products.

The Env peptides were pooled in groups of 6 peptides, totaling 20 pools, Box S1. NS peptides were arranged into matrix pools [NS1 (7×7); NS2a (8×4); NS2b (7×4); NS3 (15×10); NS4a (8×5); NS4b (4×4) and NS5 (17×15)] ensuring that each peptide was present in two different pools, Box S2 [15]. Ten NS peptides were tested individually (no pooling).

The peptides NS4b7-35, NS4b26-44, NS4b75-83, NS4b75-84 were synthesized and purified by Genescript (New Jersey, USA). The purity of these peptides was greater than 95%.

Stock solutions of all peptides were sterile-prepared at 2 mg/mL in 10% (v/v) dimethyl sulphoxide (DMSO; Sigma-Aldrich) and stored at −20°C until use.

**Cell Lines and Peptide Pulsing**

Transporter associated with antigen processing-deficient T2 cells expressing HLA-A*0201 were maintained in RPMI 1640 medium (Invitrogen, Brown Dee, WI) supplemented with 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan, UT), 1% (v/v) glutamine (Gibco, Gaithersburg, MD) and 1% (v/v) penicillin-streptomycin (Gibco, Gaithersburg, MD). For pulsing the peptides, one million target cells were washed, resuspended in 1 mL of media and incubated at 37°C for 2 h with peptides at 10 μg/mL. Cells were then washed 3 times and resuspended in SFM at 1×10⁶ cells/mL for T-cell function assays.

**ELISPOT Assay for IFN-γ**

Interferon-γ ELISPOT assays were performed by using the ELISPOT set from BD-Biosciences Pharmingen (San Diego, CA), according to the manufacturer’s protocol. Briefly, 96-well nitrocellulose-bottom plates were coated with 100 μL/well primary antibody anti-human IFN-γ at 5 μg/mL and incubated at 4°C.
overnight. The following day, plates were blocked with 200 μL/well of RPMI 1640 (Invitrogen, Brown Dec, WI) containing 10% (v/v) heat-inactivated FBS (HyClone, Logan, UT), 1% (v/v) glutamine (Gibco, Gaithersburg, MD) and 1% (v/v) penicillin-streptomycin (Gibco, Gaithersburg, MD) for 2 h at room temperature. Then, the cells were plated, in duplicate, at a range of 1–3×10^5 cells/well along with peptides at 10 μg/mL (concentration of each peptide when tested as a pool and also the concentration of individual peptides when tested individually) both in SFM. During peptide pool analysis and deconvolution, total PBMC were used as source of T-cells. For the experiments aimed to confirm whether CD8+ T-cells were driving the cellular responses, in addition to total PBMC, CD4-depleted PBMC samples were included in the analysis. Media (SFM) containing 1% (v/v) glutamine, 1% (v/v) penicillin-streptomycin alone (background) and media supplemented with phorbol 12-myristate 13-acetate (PMA; Sigma) at 250 ng/mL and ionomycin (Sigma) at 250 ng/mL were used as negative and positive controls, respectively. After 16 h incubation at 37°C, 5% CO₂, the plates were washed twice with distilled water and 4 times with PBS containing 0.05% Tween-20 (PBS-T; Sigma) followed by incubation for 2 h, at room temperature, with 4 μg/mL of biotinylated anti-human IFN-γ. Plates were again washed four times with PBS-T and incubated for 1 h, at room temperature, with avidin-horseradish peroxidase at 10 μg/mL. After another washing cycle (5×) using PBS-T followed by three washes with PBS, plates were developed with substrate 3-amino-9-ethyl carbazole (AEC; BD-Biosciences Pharmingen, San Diego, CA) for 40 min. The reaction was stopped with distilled water, the plates were air-dried and spots were counted using the ImmunoSPOT reader using ImmunoSPOT software version 3.2 (Cellular Technology Ltd.). Totals for samples were included in the analysis. Media (SFM) containing 10% (v/v) FBS (Hyclone, Logan, UT) was supplemented with 8% (v/v) T-cell growth factor (TCGF) and antibiotics, and incubated individually with HLA-A*0201/anti-hCD28 aAPCs [16,17,18] at concentration of 50×10^6 beads/mL for 5 days at 37°C. Then, one million CD8+ T-cells isolated from HLA-A*0201 positive individuals were co-cultured with 1×10^6 of each peptide-loaded aAPCs, individually, in RPMI 1640 media supplemented with 8% (v/v) T-cell growth factor (TCGF) and 5% (v/v) human AB serum. On day 4, the plates were replenished with media containing TCGF and AB human serum and cultured for 3 more days. On day 7, the aAPCs were removed and the cells were washed, counted and their concentration adjusted to 1×10^6 cells/mL in RPMI 1640 media (Invitrogen, Brown Dec, WI) supplemented with 10% (v/v) FBS (HyClone, Logan, UT).

**HLA Genotyping**

Genomic DNA was extracted from PBMCs collected from 142 volunteers by using the PureLink Genomic DNA MiniKit (Invitrogen, Carlsbad, CA). The HLA alleles genotyping was performed using the polymerase chain reaction (PCR) test-sequence-specific primer (SSP) UniTray Kit (Invitrogen, Brown Dec, WI), which provides low to intermediate HLA typing results according to the manufacturer protocol. After amplification, the PCR products were separated in 2% (w/v) agarose gel pre-stained with ethidium bromide (0.25 μg/mL gel). Gels were electrophoresed for 30 min at 150 volts in 0.5× Tris-Boric acid-EDTA (TBE) buffer, then examined under Ultraviolet illumination and documented by photography. The types of HLA-A, B, C were then determined by specific electrophoresis bands using the UniMatch Software (Invitrogen, Brown Dec, WI).

Further analysis was performed to determine the HLA allele in high-resolution for the individuals HLA-A*02 positives using the same methodology above mentioned.

**Artificial APC (aAPC) Loading and Expansion of NS4b-Specific CD8+ T-Cells**

The peptides NS4b77–85, NS4b76–84, NS4b73–81 and NS4b73–80 were incubated individually with HLA-A*0201/anti-hCD28 aAPCs [16,17,18] at concentration of 50×10^6 beads/mL for 5 days at 37°C. Then, one million CD8+ T-cells isolated from HLA-A*0201 positive individuals were co-cultured with 1×10^6 of each peptide-loaded aAPCs, individually, in RPMI 1640 media supplemented with 8% (v/v) T-cell growth factor (TCGF) and 5% (v/v) human AB serum. On day 4, the plates were replenished with media containing TCGF and AB human serum and cultured for 3 more days. On day 7, the aAPCs were removed and the cells were washed, counted and their concentration adjusted to 1×10^6 cells/mL in RPMI 1640 media (Invitrogen, Brown Dec, WI) supplemented with 10% (v/v) FBS (HyClone, Logan, UT).

**Intracellular Cytokine Staining (ICS) to Detect NS4b-Specific CD8+ T-Cell Responses**

CD8+ T-cells (1×10^5) that underwent one round of expansion with different aAPCs were “challenged” with T2 cells (1×10^5) pulsed, individually, with each NS4b peptides for 2 h at 37°C, 5% CO₂. Then, Golgi stop (BD Biosciences, San Diego, CA) was added to the culture to stop protein trafficking and secretion. The cells were cultured for 4 h at 37°C, 5% CO₂ and then washed twice with staining buffer [PBS containing 0.05% sodium azide and 2% (v/v) FBS (HyClone, Logan, UT)]. The cells were stained with anti-CD8 FITC (Sigma Aldrich, St. Louis, MO) for 20 min at 4°C and washed 3 times with staining buffer. After that, the cells were permeabilized with cytoperm/cytotox buffer (BD Biosciences, San Diego, CA) for 20 min at 4°C followed by 3 washes with perm/wash buffer (BD Biosciences, San Diego, CA). Then staining with either anti-hCD107a-PE (BD Biosciences, San Diego, CA) or anti-hIFN-γ-PE (BD Biosciences, San Diego, CA) was performed for 30 min at 4°C, after which the cells were washed twice with perm/wash buffer and once with staining buffer. Finally, the cells were acquired on a FACS Calibur flow cytometer (BD Biosciences, San Diego, CA) and the data was analyzed using Flowjo for Macintosh version 8.8.6 (Tree star, Ashland, OR).

**MHC Purification and Binding Assays**

Purification of HLA class II MHC molecules by affinity chromatography, and the performance of assays based on the inhibition of binding of a high affinity radiolabeled peptide to quantitatively measure peptide binding, were performed essential-
ly as detailed elsewhere [19,20,21,22,23]. Briefly, EBV-transformed homozygous cell lines were used as sources of MHC molecules. A high affinity radiolabeled peptide (0.1–1 nM) was co-incubated at room temperature or 37°C with purified MHC in the presence of a cocktail of protease inhibitors. Following a two-day incubation, MHC bound radioactivity was determined by capturing MHC/peptide complexes on Ab coated Lumitrac 600 plates (Greiner Bio-one, Frickenhausen, Germany), and measuring bound cpm using the TopCount (Packard Instrument Co., Meriden, CT) microscintillation counter. The concentration of peptide yielding 50% inhibition of the binding of the radiolabeled peptide was calculated. Under the conditions utilized, where [peptide] < [MHC] and IC50 >> [MHC], the measured IC50 values are reasonable approximations of the true Kd values. Each competitor peptide was tested at six different concentrations covering a 100,000-fold range, and in three or more independent experiments. As a positive control, the unlabeled version of the radiolabeled probe was also tested in each experiment.

**Statistical Analysis**

Fisher’s two-tailed test was used to associate the response against a given peptide and HLA genotype. When significant p-values were achieved (p<0.05), the odds ratio and 95% confidence intervals (CI) were calculated (R Statistical Package 2.9.0). HLA-A, B and C genotype distributions were checked with Hardy-Weinberg equilibrium. In addition, we compared the allelic distributions of the five genotyped HLA genes (HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ) to HLA genotype data obtained from the MHC Database (dbMHC) of the NCBI, consisting of two studies with Brazilian populations: one with volunteers from the state of Minas Gerais (which we refer to as “dbMHCh1”), and another with volunteers from the state of São Paulo (referred to as “dbMHCh2”). Pearson’s correlation was used to assess the correlation between HLA promiscuity and frequency of recognition of the yellow fever T-cell epitopes identified.

**Results**

**Screening of Immunogenic Peptides**

The immunogenicity of the YF-17DD peptides was determined by IFN-γ ELISPOT performed ex vivo using PBMCs from immunized volunteers. A flowchart summarizing the assays and strategies for characterization of the T-cell responses are shown in Figure 1. Blood samples were negative for anti-YF-17DD antibodies prior to vaccine inoculation and all vaccines seroconverted by one month after immunization [14]. The peptides were organized in groups corresponding to the Env, NS1, NS2, NS3, NS4 and NS5 proteins and screened in two rounds. In the first round the peptides were organized in pools or matrices and tested in samples from a series of donors as indicated in Table 1. In the second round, immunogenic peptides were selected from the pools screened individually as indicated in Table 2. Screening of immunogenic T-cell peptides within the structural proteins: The initial screening was performed with 120 peptides from the Env protein. The peptides were organized in 20 pools with six peptides in each and tested in samples from 146 volunteers. Five pools (3, 9, 14, 15 and 20) were immunogenic in 13 to 34 of the 146 individuals tested. Peptide pool number 15 was immunogenic in 34 of the 146 individuals tested and was most prevalent immunogenic pool in this population (data not shown). Thirty individual peptides from these five pools were selected for a second round of analysis and tested individually (Table 2). Thirteen peptides were positive in the second round (Table S1). Six (Env351–373, Env355–379, Env373–379, Env373–351, Env345–359 and Env361–373) out of the 30 Env peptides tested individually were positive in at least 10% the volunteers. Their protein position, amino acid sequence, frequency with in the cohort and magnitude of the ex vivo T-cell response are shown on Table 3.

Screening of immunogenic T-cell peptides within Non-structural (NS) proteins: A similar strategy was applied to screen the T-cell responses against NS peptides. In the first round, the pools were organized in matrices with each peptide being present in two pools to allow identification of the immunogenic peptide within each pool. The matrices were assembled as described in the methods section and tested in a series of samples from different volunteers (Table 1). The peptide pool matrix analysis, in many cases, allowed the precise identification of the immunogenic peptide within each pool. The peptides that most frequently activated T-cell responses in the individuals tested are shown in Table S1. These peptides were selected for the second round of screening as individual peptides in a second set of samples. The summary of the results of the second round is shown in Table 2. In total, 7 (NS1), 3 (NS2a), 6 (NS2b), 18 (NS3), 11 (NS4a), 2 (NS4b) and 13 (NS5) peptides were shown to be immunogenic on 1 to 11 vaccines tested in the second round (Table S1). Ten peptides among NS proteins (NS2b17–22, NS2b15–21, NS317–18, NS4a17–21, NS4b27–91, NS544–51, NS544–52, NS544–52, NS544–52, NS531–355) were immunogenic in at least 10% of the YF-17DD vaccinees. Their position, sequence, frequency and magnitude of T-cell response are shown on Table 3.

**Identification of HLA Class I Alleles Associated with the Most Frequently Immunogenic Peptides**

In order to investigate the HLA restriction related to the T-cell responses to each of the peptides shown on Table 3, HLA genotyping was performed for the loci HLA-A, HLA-B and HLA-C on 142 YF-17DD vaccinees (Table S2). The frequency of the HLA types present in our cohort was compared to the frequencies reported by two Brazilian blood banks (Minas Gerais - “dbMHCh1” and São Paulo - “dbMHCh2”) and deposited at the cohort dbMHC database. Statistical analysis indicated a large degree of correlation between the HLA diversity present in the study volunteers and the ones on the dbMHC database, for all available genes (p<0.01), suggesting that the HLA diversity of the cohort is representative of the general Brazilian population. The HLA types of the samples used on the second round of screening and the respective peptide with which they reacted are shown in Table S3. Subsequently, we investigated the possibility of some HLA types to be overrepresented among the individuals responding to a peptide. Indeed, some HLA types were very prevalent among the responders of some peptides. For example, HLA-A*23 was very frequent among the individuals responding to the NS541–495 peptide while it was seldom observed among individuals that did not react to this peptide suggesting the possibility that this HLA type might be involved in the presentation of an epitope present within the immunogenic 15-mer. In order to confirm these associations, Fisher’s test was carried out comparing the frequency of the HLA types present in the vaccines responding to a given peptide versus the HLA frequency in the general population or among the ones that did not respond. The HLA alleles with significant statistical associations are shown in Table 4.

Nine out of the 16 immunogenic peptides could be statistically associated with one or more HLA type. Seven peptides presented significant associations with one HLA type, four HLA-A (A*02, A*11, A*23, A*26), three HLA-B (B*15, B*18, B*39) and one HLA-C (C*12). Two peptides, Env361–373 and NS544–355 showed significant association with two HLA-types (A*26 and B*18) and (B*39 and C*12) respectively. Three immunogenic peptides
Env57–71, Env345–359 and NS4b 77–91, were associated with HLA-A*02 and other two NS5 341–355 and NS5 345–359 were associated with B*39. However these two peptides associated with B*39 overlap by 11 amino acids suggesting that these associations are likely directed to an immunogenic determinants shared by these two adjacent peptides.

Figure 1. Screening of immunogenic yellow fever peptides. Blood samples were obtained from 220 vaccinees. 653 peptides from Env and non-structural proteins were organized in pools and tested by ELISPOT assay. Then, 108 immunogenic peptides were selected from the pools and tested individually. In total, 16 peptides were positive in at least 10% the subjects. Statistical association showed that nine immunogenic peptides were associated with HLA class-I. Seven from these peptides could activate CD4⁺ depleted PBMCs from YF-17DD vaccinees ex vivo. In addition, 9–10 mers peptides covering the NS4b77–91 were cultured in CD8⁺ T-cells isolated from HLA-A*02:01-positive individuals. Four epitopes (NS4b77–85, NS4b75–83, NS4b75–84, NS4b76–84) were able to induce a specific response. Biochemical binding assays indicated that the most prevalent immunogenic peptides could bind multiple HLA-II molecules.

doi:10.1371/journal.pntd.0001938.g001
Validation of HLA Class I Association Strategy and Confirmation of HLA-A*02 CD8 T-Cell-Restricted Responses

The peptides Env57–71, Env345–359 and NS4b77–91 induced immune responses predominantly in HLA-A*02 individuals (Tables 4 and S3). In addition, the statistical analysis indicated that the peptides Env561–575, NS3127–131, NS4a141–155, NS4a145–159, NS4b165–179 and NS5141–155 were associated with the presence of the other HLA class I alleles. In order to validate these associations, we analyzed whether CD8 T-cells derived from the immunized individuals could be activated by these peptides. For these analysis, PBMCs from 3 volunteers were collected, the immunized individuals could be activated by these peptides. T-cells derived from these T-cell depleted, and the T-cell responses to each peptide measured by ELISPOT. It is important to note that some antigen presenting cells (APC) were unintentionally removed, because CD4 is also expressed on monocytes and dendritic cells, albeit at lower levels than on CD4 T helper cells. Seven of the nine peptides selected could activate CD4+ T-cells depleted PBMCs from YF-17DD vaccinees ex vivo, whereas PBMCs collected pre-vaccination were negative, corroborating the hypothesis that these immune responses are likely being mediated by CD8+ T-cells (Table 5).

In order to further determine the HLA-restriction involved on the T cell response against the peptide NS4b77–91, previously shown to be associated with HLA-A*02, all the subjects bearing this HLA were genotyped at high resolution for this locus. According to the analysis, 78% of the subjects responding against the peptide NS4b77–91 were HLA-A*02:01 (Table S3). Subsequently, all the 9-mers covering the NS4b77–91 sequence were synthesized and tested for T-cell activation on PBMC from HLA-A*0201 subjects (n= 3 per peptide). For this experiment, the initial 15-mer was used as positive control. Among the 9-mers derived from the NS4b77–91, the NS4b77–85 (LWNGPMAV) was the one that induced the most T-cell activation (NS4b77–91, used as positive control in Figure 2C). Interestingly, Akondy et al. [24] identified an immunodominant epitope HLA-A*02-restricted on NS4b protein of YF-17D vaccine, the position of which was at amino acid 76–84 (LLWNGPMA), one amino acid to N-terminal side (Figure 2A). This observation highlights one important caveat of screening peptide libraries, and points at the presence of epitopes not detected due to the manner in which the 15-mer peptides of the library were spliced. Therefore, we tested the adjacent peptide at the position 75–91 for the presence of potential HLA-A*02:01-restricted epitopes within its sequence. Since these peptides have a common core (LLNGPMA), they would represent possible products of antigen processing that could activate the same T cell clone. Thus, to investigate that these peptides could be presented by HLA-A*02:01, CD8 T-cells were isolated from HLA-A*02:01-positive individuals and the ELISPOT assay for IFN-γ was performed using T2 cells, which expresses HLA-A*02:01 exclusively, as target for T-cell activation. Figure 2B depicts representative ELISPOT data set. All peptides analyzed could activate CD8 T-cells, but to different degrees. The peptides with the core LLWNGPMA (NS4b76–84 and NS4b75–84) induced the highest number of spots, whereas the peptides in which the core was incomplete (NS4b75–85 and NS4b75–93) the T-cell response tended to be lower. Finally, we tested the ability of these peptides to expand the population of CD8 T-cells of the patients for one week using aAPC loaded with each of the NS4b peptides. One million purified CD8 T-cells were co-cultured with each aAPC (ratio 1:1) and after one week the yield of cellular proliferation of the CD8+ T-cell population expanded by the aAPCs loaded with NS4b75–84, NS4b76–84, NS4b75–81 or NS4b76–81 peptides were 2 × 10^6, 4 × 10^6, 2.5 × 10^6 and 3.5 × 10^6 respectively, indicating a proliferation of 2 to 4 fold. Flow cytometry analysis showed that after one week of expansion, epitope-specific CD8 T cells were activated, as degranulating cells (surface CD107a; data not shown) producing IFN-γ (Figure 2C) were identified upon challenging with the same epitopes used during cell expansion. Notably, the expansion of NS4b76–84-specific CD8 T-cells was the highest among the peptides tested and reached 22%. Interestingly, the peptide NS4b76–84, which on unexpanded CD8 T-cells tested ex vivo elicted comparable levels of T-cell response as NS4b76–84 had, after one week expansion with the aAPC, a frequency of NS4b76–84 specific CD8 T-cells that was 4-fold less as compared to NS4b76–84. These results suggest that there might be different products of antigen processing that could potentially be activating the same T cell clone, however at different degrees. The physiological role of these products of antigen processing for an effective T cell response needs to be further investigated.

Analysis of HLA Class II Responses

CD4+ and CD8+ responses cooperate with each other, enhancing and also regulating T-cell responses. CD4+ T-cell helper cytokine responses are required for a proper activation of

### Table 1. Summary of screening peptide pools (first round).

| Protein | No. of peptides | No. of vaccinees | No. of peptides recognized |
|---------|-----------------|-----------------|--------------------------|
| Env     | 120             | 146             | 20†                      |
| NS1     | 47              | 29              | 30                       |
| NS2a    | 32              | 52              | 27                       |
| NS2b    | 28              | 52              | 25                       |
| NS3     | 148             | 29              | 61                       |
| NS4a    | 45              | 52              | 38                       |
| NS4b    | 17              | 52              | 17                       |
| NS5     | 216             | 37              | 192                      |

The table shows a list of all yellow fever proteins mapped, total number of peptides tested for each protein (No. of peptides), volunteers (No. vaccinees) and peptides into a pool that were positive at least one subject (No. of peptides recognized).

†Env peptide pools. Twenty peptide pools were positive at least one subject.

### Table 2. Summary of screening individual peptides (second round).

| Protein | No. of peptides | No. of vaccinees | No. of peptides recognized |
|---------|-----------------|-----------------|--------------------------|
| Env     | 30              | 62              | 13                       |
| NS1     | 9               | 46              | 7                        |
| NS2a    | 3               | 59              | 3                        |
| NS2b    | 6               | 59              | 6                        |
| NS3     | 18              | 46              | 18                       |
| NS4a    | 17              | 59              | 11                       |
| NS4b    | 4               | 59              | 2                        |
| NS5     | 21              | 48              | 13                       |

The table shows a list of all yellow fever proteins mapped, total number of individual peptides tested (No. of peptides), volunteers (No. vaccinees) and individual peptides that were positive at least one subject (No. of peptides recognized).

†The most immunogenic Env pools (3, 9, 14, 15 e 20) were selected and thirty peptides (six peptides in each pool) were tested individually.

doi:10.1371/journal.pntd.0001938.t001

doi:10.1371/journal.pntd.0001938.t002
naive CD8+ T-cells [25] and CD4+ helper epitopes linked to each other can also cooperate to allow more efficient T-cell priming of weaker epitopes [26,27]. Thus, it is reasonable to expect that the most immunogenic peptides could contain both HLA-I and HLA-II binding motifs. Therefore to address this, the binding affinity of the immunogenic peptides was determined for 14 different HLA class II molecules (DRB1*0101, 0301, 0401, 0404, 0405, 0701, 0802, 0901, 1101, 1302, 1501, DRB3*0101, DRB4*0101, DRB5*0101) and the results are shown in Table 6. All the peptides tested could bind with high affinity (IC50 ≤ 1000 nM, see [28]) to at least one HLA-DR molecule. Levels of peptide promiscuity varied from low (affinity to 2 to 5 HLA class II molecules bound), e.g. NS5341–355 and NS5345–359; to intermediate (affinity to 6 to 9 HLA class II molecules bound), e.g. Env 337–351, NS2b97–111 and NS5 465–479; and highly promiscuous (binding to ≥10 HLA molecules), e.g. Env 57–71, Env 345–359, NS4b 77–91, NS5469–483, and NS5 481–495. Nine peptides (Env57–71, Env345–359, Env361–375, NS3 137–151, NS4b77–91, NS5 341–355, NS5345–359, NS5465–479 and NS5 481–495) contained overlapping HLA-I and HLA-II binding motifs (Tables 3 and 6). This suggested that our screening process targeted the identification of promiscuous T-cell antigens. We then tested whether the frequency of recognition of the peptides on the cohort was dependent on the level of promiscuity of those to different HLA-II molecules. There was a significant correlation (R² = 0.45, p = 0.01) between the number of HLA class II molecules bound to the peptides (Figure 3) and the frequency of positivity in the vaccinees, suggesting that the prevalence of the immunogenicity of an antigen in the population is associated with the HLA promiscuity of the T-cell antigen.

### Table 3. Most frequent peptides that activated T-cells from YF-17DD vaccinees.

| Peptide     | Sequence                           | (n) 2nd round | No. of responders | Recognition frequency (%) | Average ± STDEV | Median (peptide) | Median (negative control) |
|-------------|------------------------------------|---------------|-------------------|---------------------------|-----------------|------------------|---------------------------|
| Env57–71    | RKVCYNAVLTHVKIN                     | 30            | 10                | 33                        | 149 ± 248       | 48               | 2                         |
| Env59–79    | LTHVKINDCKPSTGE                     | 30            | 3                 | 10                        | 158 ± 196       | 83               | 5                         |
| Env57–87    | KCPSTGEAHLAEENE                     | 30            | 3                 | 10                        | 146 ± 153       | 60               | 2                         |
| Env57–355   | ADDLTAANKILGVT                       | 18            | 3                 | 17                        | 23 ± 10         | 28               | 3                         |
| Env345–359  | NKGLILTVNPIASTN                     | 27            | 9                 | 33                        | 72 ± 85         | 30               | 3                         |
| Env61–375   | DEVLIEVNPFFGDSY                      | 27            | 4                 | 15                        | 72 ± 88         | 35               | 9                         |
| NS2b77–111  | VAMTSLAVGAALHP                      | 59            | 6                 | 10                        | 14 ± 6          | 12               | 4                         |
| NS2d77–112  | ALLVLAGLWFHVRG                      | 22            | 3                 | 14                        | 80 ± 89         | 43               | 2                         |
| NS3137–151  | GTSGSPINNINGEVG                     | 46            | 5                 | 11                        | 90 ± 49         | 115              | 5                         |
| NS4a197–211 | TMLSPMUHHWIKEV                      | 22            | 3                 | 14                        | 140 ± 178       | 61               | 3                         |
| NS4b97–111  | LWGPNMAVSMGTOMVR                     | 59            | 11                | 19                        | 100 ± 138       | 50               | 3                         |
| NS5341–355  | RMAMTDTPFPQQQRV                     | 48            | 6                 | 12                        | 92 ± 93         | 52               | 5                         |
| NS5345–359  | TDTPFPQVRVFKKE                      | 48            | 8                 | 17                        | 336 ± 320       | 172              | 3                         |
| NS5465–479  | EFGAKGSRMAMWW                        | 48            | 6                 | 12                        | 486 ± 707       | 67               | 2                         |
| NS5469–483  | AKGSRAWYMWMGLAR                     | 48            | 8                 | 17                        | 395 ± 643       | 45               | 3                         |
| NS5581–405  | GARYLEFALEGFNE                      | 48            | 11                | 23                        | 383 ± 380       | 204              | 2                         |

(n) = Number of volunteers tested against each individual peptide.

doi:10.1371/journal.pntd.0001938.t003

### Table 4. Statistical HLA class I association analysis.

| Peptide     | HLA Association   |
|-------------|-------------------|
| Env57–71    | A*02 (OR = 3; p = 0.03) |
| Env345–359  | A*02 (OR = 5; p = 0.003) |
| Env61–375   | A*26 (OR = 9; p = 0.03) |
| NS3137–151  | A*11 (OR = 3; p = 0.03) |
| NS4b77–91   | A*02 (OR = 3; p = 0.02) |
| NS541–355   | B*39 (OR = 13; p = 0.004) |
| NS545–359   | B*39 (OR = 9; p = 0.01) |
| NS5465–479  | B*15 (OR = 5; p = 0.04) |
| NS5581–405  | A*23 (OR = 6; p = 0.001) |

Table 5. Determination of memory CD8 T-cell-restricted responses against the peptides associated with HLA class I molecules.

| Peptide     | No. of responders | IFN-γ SFC (CD4-depleted PBMCs/10⁶) |
|-------------|-------------------|------------------------------------|
| Env57–71    | 3                 | 152 ± 145                          |
| Env345–359  | 3                 | 315 ± 160                          |
| Env61–375   | 2                 | 16 ± 0                             |
| NS3137–151  | 0                 | -                                  |
| NS4b77–91   | 3                 | 101 ± 23                           |
| NS541–355   | 0                 | -                                  |
| NS545–359   | 3                 | 66 ± 71                            |
| NS5465–479  | 2                 | 168 ± 0                            |
| NS5581–405  | 2                 | 95 ± 0                             |

(–) = No response.

doi:10.1371/journal.pntd.0001938.t005
Discussion

This study presents the screening of 653 peptides of the YF-17DD Env, NS1, NS2, NS3, NS4 and NS5 proteins in the context of a cohort of healthy adults immunized with the YF-17DD vaccine. Considering the two rounds of peptide screening, each peptide was tested in at least 75 individuals, and in the case of the Env protein each peptide was tested in 208 volunteers. The

Figure 2. YF-17DD Immunodominant HLA-A*0201 restricted epitope in the NS4b protein. A. Sequences of the peptides used to identify the immunogenic nonamer epitope in NS4b. IC50 values for IEDB-AR prediction were calculated; B. PBMCs from HLA-A2 vaccinees were cultured in the presence or absence of 9-10mer (NS4b76-84, NS4b75-83, NS4b75-84) peptides. ELISPOT assay; C. Intracellular cytokine staining were performed. All peptides analyzed could activate CD8+ T-cells and the expansion of NS4b76-84-specific CD8+ T-cells was the highest among the four peptides tested. Plots gated on CD8+ T-cells for one representative donor are shown.

doi:10.1371/journal.pntd.0001938.g002

Table 6. Binding affinity in nanomols of the most frequent peptides that activated T-cells.

| Peptide       | DRB1             | DRB3          | DRB4          | DRB5          | Total DR bound |
|---------------|------------------|---------------|---------------|---------------|----------------|
|               | *0101 *0301 *0401 *0404 *0405 *0701 *0802 *0901 *1101 *1302 *1501 *0101 *0101 | *0101 *0101 *0101 |               |               |                |
| Env77-71      | 242 2579 219 1104 459 57 423 457 938 123 1846 197 306 7.4 11               |
| Env337-351    | 31 956 1795 5614 11918 32 846 68 1228 0.23 63 119 1243 853 9               |
| Env454-459    | 41 386 0.73 716 189 53 3.5 281 24 4.2 8.1 |                |                |                |
| Env651-675    | 335 100 7.0 911 387 1563 21 4314 2574 30 566 267 578 6789 10               |
| NS2b97-111    | 3.9 19386 3664 4258 23 60 222 69 6739 7214 987 9903 1183 64 7               |
| NS3137-151    | 7356 18002 - - - - 19010 15842 9476 36 6310 9292 - 7162 1               |
| NS4b77-91     | 181 84 202 2814 1329 303 348 307 2810 62 575 852 317 1281 10               |
| NS5341-355    | 1834 650 201 - - - - 11772 20 1343 11624 - 2270 12683 4835 478 9533 4               |
| NS5345-359    | 2837 6737 5694 319 180 5420 - - - - 1007 - 3551 4800 7393 2               |
| NS5465-479    | 72 5988 884 1198 1186 53 2388 428 4721 2637 450 1043 417 537 7               |
| NS5469-483    | 26 5088 2788 380 289 247 424 699 4183 1919 202 440 98 513 10               |
| NS5541-495    | 30 627 951 2898 73 40 7484 81 5925 10577 299 22 255 80 10               |
| Total Peptides bound | 9 6 7 4 7 9 7 8 2 6 8 6 8 7 |                |                |                |
| Population Frequency (%) | 9.17 7.33 13.33 - - 14.33 6.00 1.17 10.67 15.67 13.00 - - - |                |                |                |

Numbers in bold: values of IC50 below the cutoff of 1000 nmol by which determine that the peptide has affinity to the HLA molecule.

(---): not determined.

doi:10.1371/journal.pntd.0001938.t006
screening allowed the identification of 16 T-cell peptides that were immunogenic in 10% or more of the individuals tested. Only a few YF-17D epitopes have been characterized previously [12,13,24]. Overall, among the 16 immunogenic peptides identified herein, 14 contain new human T-cell antigens (Env 57–71, Env 65–79, Env 73–87, Env 337–351, Env 345–359, Env 361–375, NS2b 97–111, NS3 137–151, NS4a 197–211, NS5 341–355, NS5 345–359, NS5 465–479, NS5 469–483, NS5 481–495). Two peptides, NS2b 113–127 [12] and the NS4b 77–91 [24], contained epitopes previously described in humans, while the Env 57–71 and NS2b 113–127 peptides contain epitopes that have been described in the murine H2d background. The murine epitope (Env 57–71) was reported to be able to stimulate both CD8+ and CD4+ T-cells to secrete IFN-γ in YF-17DD vaccine immunized H2d mice and also HLA A02, B07 and A24 transgenic mice [29,30]. These highly prevalent immunogenic peptides were shown to contain multiple HLA binding motifs and that the degree of prevalence of its immunogenicity was correlated with the HLA promiscuity. Previous studies have shown some degree of correlation between predicted binding affinity and immunogenicity [30]. However, additional studies are required to determine the precise breadth and differences in functionalities of these immunogenic peptides in different HLA contexts.

Biochemical binding assays indicated that the most prevalent immunogenic peptides could bind multiple HLA molecules and the prevalence of their immunogenicity was correlated with the presence of multiple HLA binding motifs. Interestingly, the level of promiscuity of the class II binding was correlated with the prevalence of the immunogenicity of the peptide in the cohort (Figure 2).

No promiscuous T-cell immunogens (peptides that bind more than one HLA allelic variant) have been described for YF wild type virus or other flaviviruses until now. Computational strategies for determination of promiscuous HLA-I and II binding peptides [28,31] have been used for cancer [32] and infectious disease [33]. Besides the theoretical advantage of being broadly reactive in the population, the biological characteristics of promiscuous T-cell epitopes are not clear and only few promiscuous epitopes have been identified.

CD4+ T-cells play a major role in the generation of CD8+ cytotoxic T-cell responses and maturation of neutralizing antibodies [34,35,36]. In addition, virus-specific CD4+ T-cells may be able to tolerate more sequence diversity in their target epitopes than CD8+ T-cells, thus being more resistant to mutational escape [37]. Most of the immunogenic peptides, subsequently assessed using competitive binding assays bound to at least six HLA-DR alleles, indicating that an individual bearing at least one such HLA-DR molecule could develop broad CD4+ T-cell responses against the YF-17DD. Previous work has shown that many peptides are capable of binding with good affinity to multiple DR alleles [19,28,38,39,40]. However, it is still not clear how a given promiscuous peptide binds different HLA class II molecules. For example, Kilgus et al. [41] showed that distinct sites on the malaria T-cell epitope interact in different ways with the three DR molecules analyzed [41]. On the other hand, Panina-Bordignon et al. [42] showed that promiscuous peptides interact in a similar way with different DR molecules, possibly by binding to the conserved DR residues [42]. Chicz et al. [43] suggested that the ability of peptides to bind multiple HLA alleles must depend on the composition and location of several key amino acids within the primary structure, which led to the hypothesis that rigid allele-specific motifs for the class II molecule do not exist, thus permitting a broad binding specificity [43]. To our knowledge, the present study is the first report showing that the frequency of recognition of the peptides is dependent on the level of promiscuity of those to different HLA molecules. The exact role of the promiscuous peptides in protective immune response still un-
known, however one would expect that a vaccine built with multiple immunodominant promiscuous epitopes, capable to bind several HLA molecules, could lead to an increased coverage of the human population. Although the cellular and humoral responses play a central role in effectiveness of YF vaccines, the innate immunity, which is known to shape the development of adaptive immune responses, also contribute to vaccine-mediated protection through other mechanisms, including its live replicative nature and its ability to trigger several Toll-like receptors [6]. In conclusion, the identification of this set of highly prevalent class I and II T-cell epitopes will enable detailed studies of the role of T-cell responses on the development of yellow fever immunity and the identification of the structural requirements of immunogenic promiscuous T-cell epitopes.

Supporting Information

Table S1 List of Env and NS peptides sequences that activated T-cells from YF-17DD vaccinees and their responses.

Table S2 List of the HLA genotypes of the YF-17DD vaccinees.

References

1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981) Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 893–900.
2. Querec T, Bennouna S, Alkan S, Laaer A, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyclonal immunity. J Exp Med 203: 413–424.
3. Monath TP (2005) Yellow fever vaccine. Expert Rev Vaccines 4: 533–574.
4. Barrett AD, Teuwen DE (2009) Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21: 308–315.
5. Reinhardt B, Jasper R, Niedrig M, Kosten C, L’Age-Stehr J (1998) Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159–167.
6. Paleldra B (2009) Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9: 741–747.
7. Yauch LE, Zellweger RM, Koturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dendrige virus-specific CD8+ T cells. J Immunol 182: 4863–4873.
8. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, et al. (2010) CD4+ T cells are not required for the induction of dendrige virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185: 5405–5416.
9. Querc T, Akondy RS, Lee EK, Gao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116–125.
10. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119–3131.
11. Co MD, Kilpatrick ED, Rothman AL (2009) Dynamics of the CD8+ T-cell response following yellow fever virus 17D immunization. Immunology 128: 717–727.
12. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL (2002) Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B8-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293: 151–163.
13. Gu R, Nougarde N, Begue S, Sanchez V, Soung N, et al. (2008) Cell-mediated immunity induced by chimeric etiovalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712–5721.
14. de Melo AB, da Silva Mda P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, et al. (2011) Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739–747.
15. Roederer M, Koup RA (2003) Optimized determination of T cell epitope responses. J Immunol Methods 274: 221–228.
16. Oelke M, Krueger G, Giuntoli RL 2nd, Schneck JP (2003) Artificial antigen-presenting cellular solutions for real diseases. Trends Mol Med 11: 412–420.
32. Kobayashi H, Lu J, Celis E (2001) Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61: 7577–7584.
33. Panigada M, Sturniolo T, Besozzi G, Bocciere MG, Sinigaglia F, et al. (2002) Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect Immun 70: 79–85.
34. Matloubian M, Concepcion RJ, Ahmed R (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056–8063.
35. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205–2213.
36. Bevan MJ (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595–602.
37. Wilson DB, Wilson DH, Schroder K, Pinilla C, Blondelle S, et al. (2004) Specificity and degeneracy of T cells. Mol Immunol 40: 1047–1055.
38. Ribeiro SP, Rosa DN, Fonseca SG, Mairena EC, Postol E, et al. (2010) A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 5: e11072.
39. O’Sullivan D, Arrhenius T, Sidney J, Del Guercio MF, Albertson M, et al. (1991) On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol 147: 2663–2669.
40. Hammer J, Vaasaninen P, Tolba K, Bolen D, Higelin J, et al. (1993) Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197–203.
41. Kľugas J, Jardezyk T, Gorza JC, Trzeciak A, Gillesen D, et al. (1991) Analysis of the permissive association of a malaria T cell epitope with DR molecules. J Immunol 146: 307–315.
42. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237–2242.
43. Chiez RM, Urban RG, Gorga JC, Vignali DA, Lane WS, et al. (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178: 27–47.